Biotech Startups

CellDom develops CloneXplorer, a live single-cell assay platform combining functional imaging, molecular readouts, and integrated cell retrieval for high-resolution cell analysis. The platform enables CAR T-cell potency testing, antibody/TCR discovery, cell line development, and precision medicine applications for research and therapeutic development teams.

3 investors

Cellens develops a non-invasive, urine-based cancer diagnostics platform (Octosense) that uses nanoscale atomic-force imaging of single-cell biophysical markers combined with machine learning to detect cancer, with early data focused on bladder cancer detection. It applies mechanobiology and label-free cell analysis to cancer screening.

3 investors

Celleste Bio develops a cell-based "cocoa technology" combining biotech, agtech, and AI to produce real cocoa ingredients—including cocoa butter and powder—at scale independent of geography and climate. Its products serve as drop-in replacements for conventional cocoa in chocolate manufacturing.

3 investors

Cellivate develops animal-free cell growth solutions for cell culture and biomanufacturing, offering an extracellular vesicle (EV)-based alternative to Fetal Bovine Serum (FBS). Its products target academic, industrial, and clinical labs performing advanced cell culture and biomanufacturing.

3 investors

Cellply develops VivaCyte, an automated platform that combines microfluidic consumables, an instrument, and image-analysis software to characterize cell therapies at single-cell resolution. It serves cell therapy discovery and development teams, measuring phenotype and function across thousands of single-cell co-cultures and comparing up to 128 conditions per run.

3 investors

Cellsonics provides cell dissociation technology for research scientists using acoustic waveforms to isolate cells from tissue with higher biological relevance than conventional methods.

3 investors

Cellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.

3 investors

Cemvita uses proprietary microbial strains it calls xtremophiles to convert carbon waste into usable resources, applying synthetic biology to heavy industry and biorefining. Its work spans regenerative bio-inputs for agriculture and circular-economy processes for industrial applications.

3 investors

CenExel operates a network of clinical research centers that conduct trials and studies to advance new medical treatments. The company serves pharmaceutical sponsors, biotech firms, and patients by providing clinical research infrastructure and expertise across 18 sites in the United States.

3 investors

Centerline Biomedical develops IOPS®, a 510(k)-cleared endovascular navigation technology that provides real-time 3D image guidance for physicians performing catheterization and other endovascular procedures. The technology is designed to reduce radiation exposure and improve procedural accuracy for interventional cardiologists, vascular surgeons, and other interventionalists.

3 investors

Ceretype develops brain imaging and analysis tools that provide insights into brain circuitry for therapeutic development and clinical care of psychiatric and neurological disorders. The company serves the healthcare ecosystem including pharmaceutical companies, clinicians, and research organizations.

3 investors

Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis. The company focuses on anti-fibrotic and anti-inflammatory treatments for patients with fibrotic diseases.

3 investors

ChemT builds CelMo, an AI-driven virtual cell platform that models cell states and predicts responses to process, genetic, and molecular changes to optimize biomanufacturing. It applies this to CHO cells for antibody/protein production and T cell therapy manufacturing (including its Chemplify small molecule), serving biopharma teams working on cell line and process development.

3 investors

Chimera develops engineered cell therapies for cancer that produce therapeutic proteins only upon encountering tumor cells, using natural biological control mechanisms to improve safety and efficacy. The company focuses on treating solid tumors and other currently incurable cancers through localized, controlled immune cell activation.

3 investors

3 investors

CiRC Biosciences develops cellular reprogramming therapies that convert fibroblasts directly into specific neurons and cell types lost in degenerative eye and brain diseases. Its programs target dopaminergic neurons in Parkinson's disease, GABAergic interneurons in refractory epilepsy, and orexin neurons in treatment-resistant narcolepsy, building on prior retinal cell replacement work.

3 investors

Circular Genomics develops a proprietary platform using circular RNA biomarkers to enable early detection and understanding of neurological diseases through blood tests. The company serves researchers, clinicians, and biopharma partners with diagnostic tools for conditions like Alzheimer's and Parkinson's.

3 investors

Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy. It serves patients with chronic blinding eye diseases and operates from Cambridge, Massachusetts and Singapore.

3 investors

3 investors

Clarametyx develops novel immune-enabling therapeutics targeting bacterial biofilms to modify disease progression in patients with chronic respiratory diseases.

3 investors

Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.

3 investors

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas. The immuno-oncology company is running a Phase 1 trial (GUARDIAN-101) of its lead candidate CLSP-1025 for hard-to-treat cancers.

3 investors

Clean Food Group is a UK-based food tech company that uses fermentation to produce sustainable, function-specific oils and fats as alternatives to traditional ingredients for food, cosmetics, and pet food manufacturers. The company's proprietary CLEAN OilCell™ platform transforms food waste into high-performance ingredients at competitive prices and with reduced environmental impact.

3 investors

Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia. Its investigational therapies target patients with limited treatment options.

3 investors